Table of Contents
Epidemiology Research International
Volume 2013, Article ID 490309, 9 pages
http://dx.doi.org/10.1155/2013/490309
Review Article

Benfluorex and Mortality: A Fresh Perspective

1MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
2NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Windmill Road, Oxford OX3 7LD, UK

Received 6 June 2013; Accepted 19 November 2013

Academic Editor: Jaume Marrugat

Copyright © 2013 Nicholas C. Harvey and Andrew Judge. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Mullard, “Mediator scandal rocks French medical community,” The Lancet, vol. 377, no. 9769, pp. 890–892, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Iung, G. Baron, E. G. Butchart et al., “A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease,” European Heart Journal, vol. 24, no. 13, pp. 1231–1243, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. V. T. Nkomo, J. M. Gardin, T. N. Skelton, J. S. Gottdiener, C. G. Scott, and M. Enriquez-Sarano, “Burden of valvular heart diseases: a population-based study,” The Lancet, vol. 368, no. 9540, pp. 1005–1011, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Enriquez-Sarano, J. Avierinos, D. Messika-Zeitoun et al., “Quantitative determinants of the outcome of asymptomatic mitral regurgitation,” The New England Journal of Medicine, vol. 352, no. 9, pp. 875–883, 2005. View at Google Scholar · View at Scopus
  5. J. R. Ribera, R. Casañas Muñoz, N. Anguerra Ferrando, N. Batalla Sahún, A. Castro Cels, and R. Pujadas Capmany, “Valvular heart disease associated with benfluorex,” Revista Espanola de Cardiologia, vol. 56, no. 2, pp. 215–216, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Etienne, Y. Jobic, I. Frachon, M. Fatemi, P. Castellant, and I. Quintin-Roué, “Mitral and aortic valvular disease associated with benfluorex use,” Journal of Heart Valve Disease, vol. 20, no. 3, pp. 348–350, 2011. View at Google Scholar · View at Scopus
  7. K. Boutet, I. Frachon, Y. Jobic et al., “Fenfluramine-like cardiovascular side-effects of benfluorex,” European Respiratory Journal, vol. 33, no. 3, pp. 684–688, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Noize, M. Sauer, P. Bruneval et al., “Valvular heart disease in a patient taking benfluorex,” Fundamental and Clinical Pharmacology, vol. 20, no. 6, pp. 577–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Weill, M. Païta, P. Tuppin et al., “Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 12, pp. 1256–1262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Frachon, Y. Etienne, Y. Jobic, G. Le Gal, M. Humbert, and C. Leroyer, “Benfluorex and unexplained valvular heart disease: a case-control study,” PLoS ONE, vol. 5, no. 4, Article ID e10128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Tribouilloy, D. Rusinaru, P. Henon et al., “Restrictive organic mitral regurgitation associated with benfluorex therapy,” European Journal of Echocardiography, vol. 11, no. 7, pp. 614–621, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Tribouilloy, D. Rusinaru, S. Maréchaux et al., “Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study,” Circulation, vol. 126, no. 24, pp. 2852–2858, 2012. View at Publisher · View at Google Scholar
  13. G. Derumeaux, L. Ernande, A. Serusclat et al., “Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus,” PLoS ONE, vol. 7, no. 6, Article ID e38273, 2012. View at Publisher · View at Google Scholar
  14. E. Bondon-Guitton, G. Prévôt, A. Didier, and J. Montastruc, “Pulmonary arterial hypertension and benfluorex: 5 case reports,” Therapie, vol. 66, no. 2, pp. 135–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Savale, M. C. Chaumais, V. Cottin et al., “Pulmonary hypertension associated with benfluorex exposure,” European Respiratory Journal, vol. 40, no. 5, pp. 1164–1172, 2012. View at Publisher · View at Google Scholar
  16. C. Tribouilloy, A. Jeu, S. Maréchaux, Y. Jobic, D. Rusinaru, and M. Andréjak, “Benfluorex and valvular heart disease,” Presse Medicale, vol. 40, no. 11, pp. 1008–1016, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Boutet, “Cardiovascular complications and norfenfluramine exposure with benfluorex use,” European Respiratory Journal, supplement 52, p. 261s, 2008. View at Google Scholar
  18. C. Hill, “Number of deaths attributable to benfluorex,” Presse Medicale, vol. 40, no. 5, pp. 462–469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Fournier and M. Zureik, “Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France,” Pharmacoepidemiology and Drug Safety, vol. 21, no. 4, pp. 343–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Tuppin, L. de Roquefeuil, A. Weill, P. Ricordeau, and Y. Merlière, “French national health insurance information system and the permanent beneficiaries sample,” Revue d'Epidemiologie et de Sante Publique, vol. 58, no. 4, pp. 286–290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Weill, M. Païta, P. Tuppin, and M. Piolot, Benfluorex, Valvular Heart Disease and Mortality, French National Health Insurance Agency for Wage Earners (CNAMTS), Department of Study and Statistics Strategies (DSES), Department of Studies on Diseases and Patients (DEPP), 2010.
  22. A. Weill, M. Païta, P. Tuppin, and M. Piolot, Addendum Addressed to Afssaps: Benfluorex and Mortality, French National Health Insurance Agency for Wage Earners (CNAMTS), Department of Study and Statistics Strategies (DSES), Department of Studies on Diseases and Patients (DEPP), 2010.
  23. F. Le Ven, C. Tribouilloy, G. Habib et al., “Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry,” European Journal of Echocardiography, vol. 12, no. 4, pp. 265–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Boudes, C. Lavoute, J. Avierinos et al., “Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease,” European Journal of Echocardiography, vol. 12, no. 9, pp. 688–695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. W. A. Zoghbi, M. Enriquez-Sarano, E. Foster et al., “Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and doppler echocardiography,” Journal of the American Society of Echocardiography, vol. 16, no. 7, pp. 777–802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Weill, M. Païta, P. Tuppin, and M. Piolot, Benfluorex, valvulopathies cardiaques et décès, 2010.
  27. J. Acar, Benfluorex, valvulopathy et deces: Un autre regard, et addendum, 2011.
  28. S. T. Mast, J. G. Jollis, T. Ryan, K. J. Anstrom, and J. L. Crary, “The progression of fenfluramine-associated valvular heart disease assessed by echocardiography,” Annals of Internal Medicine, vol. 134, no. 4, pp. 261–266, 2001. View at Google Scholar · View at Scopus
  29. C. F. Dahl, M. R. Allen, P. M. Urie, and P. N. Hopkins, “Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals,” BMC Medicine, vol. 6, article 34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Koenig, “Factors associated with grade 1 or higher aortic and/or mitral regurgitation in patients exposed to benfluorex,” in Epidemiology, 2011. View at Google Scholar
  31. M. G. Baker, L. T. Barnard, A. Kvalsvig et al., “Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study,” The Lancet, vol. 379, no. 9821, pp. 1112–1119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Petousis-Harris, C. C. Grant, F. Goodyear-Smith et al., “What contributes to delays? The primary care determinants of immunisation timeliness in New Zealand,” Journal of Primary Health Care, vol. 4, no. 1, pp. 12–20, 2012. View at Google Scholar · View at Scopus
  33. R. A. Cooper, M. A. Cooper, E. L. McGinley, X. Fan, and J. T. Rosenthal, “Poverty, wealth, and health care utilization: a geographic assessment,” Journal of Urban Health, vol. 89, no. 5, pp. 828–847, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. E. R. Cheng and D. A. Kindig, “Disparities in premature mortality between high- and low-income US counties,” Preventing Chronic Disease, vol. 9, Article ID 110120, 2012. View at Publisher · View at Google Scholar
  35. R. O. Bonow, D. R. Rosing, and C. L. McIntosh, “The natural history of asymptomatic patients with aortic regurgitation and normal left ventricular function,” Circulation, vol. 68, no. 3, pp. 509–517, 1983. View at Google Scholar · View at Scopus
  36. R. Rosenhek, T. Binder, G. Porenta et al., “Predictors of outcome in severe, asymptomatic aortic stenosis,” The New England Journal of Medicine, vol. 343, no. 9, pp. 611–617, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Rosenhek, R. Zilberszac, M. Schemper et al., “Natural history of very severe aortic stenosis,” Circulation, vol. 121, no. 1, pp. 151–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. D. C. Radley and C. Schoen, “Geographic variation in access to care—the relationship with quality,” The New England Journal of Medicine, vol. 367, no. 3, p. 6, 2012. View at Publisher · View at Google Scholar
  39. A. Fagot-Campagna, I. Romon, S. Fosse, and C. Roudier, Prévalence et incidence du diabète, et mortalité liée au diabète en France—Synthèse épidémiologique, Institut de veille sanitaire, Saint Maurice, France, 2010.
  40. M. Enriquez-Sarano, C. W. Akins, and A. Vahanian, “Mitral regurgitation,” The Lancet, vol. 373, no. 9672, pp. 1382–1394, 2009. View at Publisher · View at Google Scholar · View at Scopus